Edwards Lifesciences Corporation: EPS $0.80 vs $0.737 expected; revenue $1.72B vs $1.68B
Key Facts
Q3 FY2026 results
| Metric | Actual | Estimate | Surprise | Year ago |
|---|---|---|---|---|
| EPS (USD) | 0.800 | 0.737 | +8.5% | 0.670 |
| Revenue (USD bn) | 1.720 | 1.680 | +2.3% | 1.550 |
Recent reports: actual vs estimate
| Reported | Period | EPS (USD) | Estimate | Surprise | Revenue (USD bn) | Estimate | Surprise |
|---|---|---|---|---|---|---|---|
| Nov 4, 2026 | Q3 FY2026 | 0.80 | 0.737 | +8.5% | 1.72 | 1.68 | +2.3% |
| Jul 23, 2026 | Q2 FY2026 | 0.78 | 0.743 | +5.0% | 1.74 | 1.70 | +2.4% |
| Apr 23, 2026 | Q1 FY2026 | 0.78 | 0.729 | +7.0% | 1.65 | 1.60 | +3.2% |
| Feb 10, 2026 | Q4 FY2025 | 0.58 | 0.618 | −6.1% | 1.57 | 1.55 | +1.5% |
| Oct 30, 2025 | Q3 FY2025 | 0.67 | 0.596 | +12.4% | 1.55 | 1.50 | +3.7% |
| Jul 24, 2025 | Q2 FY2025 | 0.67 | 0.624 | +7.4% | 1.53 | 1.49 | +3.0% |
| Apr 23, 2025 | Q1 FY2025 | 0.64 | 0.596 | +7.4% | 1.41 | 1.40 | +0.9% |
| Feb 11, 2025 | Q4 FY2024 | 0.59 | 0.551 | +7.1% | 1.39 | 1.36 | +2.0% |
Source: Figures from the EL7 database. Estimates are the analyst consensus carried by our data vendor (FMP), not official figures.
Edwards Lifesciences Corporation results: EPS $0.80 vs $0.737 expected; revenue $1.72B vs $1.68B. The results cover the company's Q3 FY2026. EPS came in above analysts' estimate by 8.5%; revenue above the estimate by 2.3%.
Revenue was up 10.5% from $1.55 billion a year earlier (Q3 FY2025). EPS was up 19.4% from $0.67 a year earlier. On its record, EPS topped analysts' estimates in 6 of 7 earlier comparable reports.
What the results mean
According to the company's results release, management revised its financial outlook, raising some items and lowering others.
Edwards Lifesciences Corporation’s results reflect growth across its businesses and regions, with transcatheter aortic valve replacement remaining the core activity. The release linked procedure growth to greater physician attention to the therapy and evidence supporting proactive management of severe aortic stenosis, while selling prices remained stable globally. This highlights treatment adoption and product uptake as drivers of sales growth.
Mitral and tricuspid therapies are gaining importance within the portfolio as repair and replacement technologies expand their adoption. The range of treatments allows physicians to tailor care to patient needs and anatomy, while regulatory approvals and features that simplify device placement support access and adoption.
The surgical business benefited from continued adoption of its surgical tissue portfolio, alongside products addressing pediatric heart patients’ needs. Management emphasized its structural heart focus, disciplined execution, and sustained investment in innovation and clinical evidence as drivers of business progress. Translating that progress into routine hospital use is central to understanding the durability of growth.
What to watch on the earnings call: The pace of aortic valve replacement procedures and adoption of proactive treatment, the effect of updated American coverage policy and dedicated Japanese reimbursement on access, uptake of mitral and tricuspid therapies following regulatory approvals, the role of physician training in product rollouts, and how new clinical evidence translates into treatment practices.
For the full analysis of Edwards Lifesciences Corporation stock — valuation, scores and financial statements — see the stock page linked with this story.